Micardis
Trademark details
Micardis® is a registered trademark used for Pharmaceutical Preparations, Namely, Cardiovascular Preparations and owned by Boehringer Ingelheim KG. Full trade mark registration details, registered images and more information below.
| Goods and/or Services: | Pharmaceutical Preparations, Namely, Cardiovascular Preparations |
| Serial Number: | 75144120 |
| Registration Number: | 2237153 |
| Filing Date: | Aug 2, 1996 |
|
Last Applicant(s)/ Owner(s) of Record | Boehringer Ingelheim KG6507 Ingelheim Am Rhein DE |
| Related Products: | Pharmaceuticals |
Web Sites
powered by 
Total : 2,780,000 View more »
MICARDIS Telmisartan Tablets - Hypertension Medication
MICARDIS(R) (telmisartan) Tablets is a once-daily prescription medication that controls high blood pressure. Learn more about what it can do for you. MICARDIS is a ...
Micardis Official FDA information, side effects and uses.
Accurate, FDA approved Micardis information for healthcare professionals and patients - brought to you by Drugs.com.
Micardis Information from Drugs.com
Micardis (telmisartan) is used to treat high blood pressure (hypertension). Includes Micardis side effects, interactions and indications.
Telmisartan - Wikipedia, the free encyclopedia
Other trials include PRISMA (Protective Randomized Investigation of the Safety and efficacy if Micardis vs.Ramipril using ABPM), TRENDY (Telmisartan vs. Ramipril in renal ...
Web Sites

Total : 15 View more »
Micardis approved to reduce cardiovascular risk — Irish Medical Times
...MIMS Ireland / New clinical evidence / Micardis approved to reduce cardiovascular risk Micardis approved to reduce cardiovascular risk...that the European Commission has approved Micardis (telmisartan) for the reduction of cardiovascular...
SpeedyHealth-The Online pharmacy.Buy prescription medications online from US.
...Lyrica Macrobid Medrol Meloxicam Meridia Mesalamine Metformin Metoprolol Tartrate Micanol Micardis Micardis Plus Minocin MR Minocycline Mirapex Mobic Modrenal Namenda Naprosyn E Naproxen Nasacort...
RxUSA Pharmacy, Prescriptions, Drugs, Medications, Pharmacy
... Digoxin Diovan Diovan HCT Furosemide Hydrochlorothiazide Hyzaar Lasix (or generic) Metoprolol Micardis Nadolol Niaspan Norvasc (or generic) Plavix Toprol (or generic) Warfarin Abraxane Adriamycin Activase...
life of viagra lifestyles viagra lifting weights on viagra light sensitivity with viagra light...
...cialis together taking viagra and l caradine taking viagra and micardis taking viagra and pumping my penis taking viagra and tagament...classification mayo viagra drug company viagra drug interaction with micardis hct viagra drug interactions and side effects viagra drug scams...
News and Blogs

Total : 31 View more »
The Future of the Active, Smart and Sustainable Packaging Industry in the BRIC Countries | SYS-CON
...Completion of Qualifying Transaction Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion Hercules Offshore Announces Closing of the Ocean Columbia Acquisition IDT...
Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018 | PRLog
...in 2012. Other ARBs losing their patent exclusivity include Micardis (telmisartan) in 2014 and Benicar (olmesartan) ...forecast period, such as Diovan and Avapro (ARBs) in 2012, Micardis in 2014, Benicar in 2016 and the DRI Tekturna in 2018...
FDA Approves New Use for Boehringer Ingelheim Corporation's Micardis(R) in Cardiovascular Risk
...Boehringer Ingelheim Corporation's (JOBS) Micardis(R) in Cardiovascular Risk...its angiotensin II receptor blocker (ARB) Micardis(R...angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient...
Clinical benefit of ARBs ‘less robust’ | Australian Doctor
...their effectiveness at pre venting vascular events. The trial of 6000 ACE-intolerant people showed the ARB telmisartan (Micardis) had no significant effect on the combination of cardiovas cular death, MI, stroke or hospi talisation for heart failure...
